Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
PIK3CA and lung cancer are reported together in 4 articles.
Gene
PIK3CA
- HGNC
- HGNC:8975
77articles
77mentions
4variants with confirmed gene link
Most co-reported phenotypes (articles)
breast cancer 20colorectal cancer 16thyroid cancer 8lung cancer 4diabetes mellitus 3hepatocellular carcinoma 2ovarian cancer 2asthma 1
Reported variants (articles · ClinVar status)
Phenotype
Lung cancer
398articles
398mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
4 records shown · first 60Thymol and Carvacrol: Molecular Mechanisms, Therapeutic Potential, and Synergy With Conventional Therapies in Cancer Management.
PMID 40964147 | PMCID PMC12436185 | DOI 10.1002/fsn3.70936 · Food science & nutrition · 2025 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PIK3CA | “Thymol derivatives, such as 1,2,3-triazoles and carvacrol, effectively target breast cancer (BC) through PI3K/AKT/mTOR and NOTCH pathways and inhibit PIK3CA expression.” | 0.98 | hgnc_dict_v1 |
| phenotype | lung cancer | “In lung cancer (LC), they act as SphK1 inhibitors in NSCLC H1299 and A549 cell lines.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | XIAP | “They upregulate pro-apoptotic genes (Bax, Bak, Bid, p53, and SIVA) while downregulating anti-apoptotic genes (Bcl-2, Bcl-xL, XIAP, and cIAP1), leading to apoptosis and cell cycle arrest at G0/G1 and G2/M phases.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Thymol derivatives, such as 1,2,3-triazoles and carvacrol, effectively target breast cancer (BC) through PI3K/AKT/mTOR and NOTCH pathways and inhibit PIK3CA expression.” | 0.98 | phenotype_alias_lexicon_v2 |
Structure-Based In Silico Approaches Reveal IRESSA as a Multitargeted Breast Cancer Regulatory, Signalling, and Receptor Protein Inhibitor.
PMID 38399423 | PMCID PMC10891917 | DOI 10.3390/ph17020208 · Pharmaceuticals (Basel, Switzerland) · 2024 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PIK3CA | “In our research, we conducted a comprehensive screening using HTVS, SP, and XP, followed by an MM/GBSA computation of human-approved drugs targeting HER2/neu, BRCA1, PIK3CA, and ESR1.” | 0.98 | hgnc_dict_v1 |
| phenotype | lung cancer | “IRESSA is FDA-approved for lung cancer, which shares some pathways with breast cancers, clearing the hurdles of multitargeted drugs against breast and lung cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | BRCA1 | “In our research, we conducted a comprehensive screening using HTVS, SP, and XP, followed by an MM/GBSA computation of human-approved drugs targeting HER2/neu, BRCA1, PIK3CA, and ESR1.” | 0.98 | hgnc_dict_v1 |
| gene | ESR1 | “In our research, we conducted a comprehensive screening using HTVS, SP, and XP, followed by an MM/GBSA computation of human-approved drugs targeting HER2/neu, BRCA1, PIK3CA, and ESR1.” | 0.98 | hgnc_dict_v1 |
Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.
PMID 33956842 | PMCID PMC8101740 | DOI 10.1371/journal.pone.0251080 · PloS one · 2021 · 6 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PIK3CA | “851 cases of non-small cell lung cancer cases were profiled for the presence of biomarkers EGFR, KRAS, BRAF, and PIK3CA mutations by SNaPshot/sizing genotyping.” | 0.98 | hgnc_dict_v1 |
| phenotype | lung cancer | “Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | EGFR | “Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.” | 0.98 | hgnc_dict_v1 |
| gene | ROS1 | “EGFR, ALK, ROS1) and checkpoint inhibitors such anti-PD-1 and PD-L1 immunotherapies are being used to treat lung cancer patients.” | 0.98 | hgnc_dict_v1 |
Molecular profiling of non-small cell lung cancer.
PMID 32756609 | PMCID PMC7406040 | DOI 10.1371/journal.pone.0236580 · PloS one · 2020 · 6 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PIK3CA | “833 samples of non-small cell lung cancer from 799 patients who received resection of their lung cancer, were selected for molecular analysis of six known mutations, including EGFR, KRAS, BRAF, PIK3CA, HER2 and ALK.” | 0.98 | hgnc_dict_v1 |
| phenotype | lung cancer | “Molecular profiling of non-small cell lung cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | EGFR | “833 samples of non-small cell lung cancer from 799 patients who received resection of their lung cancer, were selected for molecular analysis of six known mutations, including EGFR, KRAS, BRAF, PIK3CA, HER2 and ALK.” | 0.98 | hgnc_dict_v1 |
| gene | KRAS | “833 samples of non-small cell lung cancer from 799 patients who received resection of their lung cancer, were selected for molecular analysis of six known mutations, including EGFR, KRAS, BRAF, PIK3CA, HER2 and ALK.” | 0.98 | hgnc_dict_v1 |